The Value of a Ready-To-Use Antibody presented by Chris Rhodes of Leica Biosystems. An RTU in a clinical setting is defined as able to dispense with minimal, if any, effort or preparation. It is important to remember this definition. Ready-to-use products offer many advantages, including the removal of variability of quality, which naturally will occur when a user is required to prepare a reagent.
Novocastra p16 antibody demonstrated an agreement of 98% with the Roche p16 antibody The study compared the percentage agreement rates of Novocastra’s p16 (6H12) IVD solution with Roche CINtec® Histology p16 assay on 170 oropharyngeal cancer cases.
New Study Shows BOND-III up to 40% Faster Than BenchMark ULTRA: In a recent study, the Leica Biosystems BOND-III was found to complete cases up to 100 minutes faster than the Roche Tissue Diagnostics BenchMark ULTRA. The study examines the panel turnaround...
